Galectin Therapeutics reported $93.42M in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
AbbVie USD 62.48B 2.05B Jun/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Galectin Therapeutics USD 93.42M 9.08M Jun/2024
Gilead Sciences USD 23.82B 17M Sep/2026
Immunic USD 0 0 Jun/2024
Incyte USD 28.42M 994K Jun/2026
Merck USD 49.69B 1.39B Sep/2026